The pharmaceutical and biotechnology sub-sectors may benefit under a Republican president and Congress as the industries are less at risk of price controls that Democrats vowed to impose. However, the GOP is vulnerable to losing majorities in both houses of Congress in the upcoming 2018 mid-term elections.
“It was hard to get a read on if drug pricing was going to hurt big name drugs and benefit generics or how mergers would best be pulled off by big firms to keep their businesses moving in the right direction,” notes InvestorPlace. “In this kind of environment, sometimes it can be a curse to have too many options to choose from at your disposal. But not for the crew at VHT.”
VHT charges just 0.1% per year, or $10 on a $10,000 investment.
For more information on the healthcare sector, visit our healthcare category.